Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sierra Sees Momelotinib ‘Sweet Spot’ In Anemic Myelofibrosis Population

Executive Summary

Sierra announced Phase III results for the JAK inhibitor in anemic myelofibrosis patients with previous JAK exposure, a difficult-to-treat population. Trial investigator Ruben Mesa talked to Scrip about some of the advantages.

You may also be interested in...



CTI Bites Off Big Chunk Of Myelofibrosis Market With Vonjo Approval

The accelerated approval for the JAK2/IRAK1 inhibitor, CTI’s first commercial product, carves out an underserved market accounting for about one-third of the US myelofibrosis population.

Finance Watch: IPOs At A Standstill As US Biotech Stock Valuations Plummet

There have been no biopharma initial public offerings in the US since 12 January while the industry’s valuations have plummeted by double digits since the start of 2022. Nevertheless, venture capital investment continues at a fast pace and there have been some follow-on public offerings.

Sierra Believes It Can Do Better Than Gilead With JAK Inhibitor Momelotinib

With many on the executive team who worked on the drug previously, Sierra thinks the stalled Phase III compound could be differentiated from Jakafi and others in the myelofibrosis space based on anemia benefit.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145768

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel